Milica Živanić

Milica Živanić

Auto-generated profile, based on publicly available information

Milica Živanić

PlasmaMED Lab Biomaterials Biomechanics and Tissue Engineering Group Department of Materials Science and Engineering and Institute for Research and Innovation in Health (IRIS) Universitat Politècnica de Catalunya BarcelonaTech (UPC) Av. Eduard Maristany 10–14 Barcelona 08019 Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Advanced Science
Verified
Journal Article
Open access
MŽMilica Živanić
Milica Živanić
AEAlbert Espona-Noguera
Albert Espona-Noguera
Abraham LinAbraham Lin
Abraham Lin
Cristina CanalCristina Canal
Cristina Canal
Cold atmospheric plasma (CAP) is a partially ionized gas that gains attention as a well‐tolerated cancer treatment that can enhance anti‐tumor immune responses, which are important for durable therapeutic effects. This review offers a comprehensive and critical summary on the current understanding of mechanisms in which CAP can assist anti‐tumor immunity: induction of immunogenic cell death, oxidative post‐translational modifications of the tumor and its microenvironment, epigenetic regulation of aberrant gene expression, and enhancement of immune cell functions. This should provide a rationale for the effective and meaningful clinical implementation of CAP. As discussed here, despite its potential, CAP faces different clinical limitations associated with the current CAP treatment modalities: direct exposure of cancerous cells to plasma, and indirect treatment through injection of plasma‐treated liquids in the tumor. To this end, a novel modality is proposed: plasma‐treated hydrogels (PTHs) that can not only help overcome some of the clinical limitations but also offer a convenient platform for combining CAP with existing drugs to improve therapeutic responses and contribute to the clinical translation of CAP. Finally, by integrating expertise in biomaterials and plasma medicine, practical considerations and prospective for the development of PTHs are offered.

1 February 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
DTDong-Jiunn Jeffery Truong
Dong-Jiunn Jeffery Truong
JGJulian Geilenkeuser
Julian Geilenkeuser
SWStephanie Victoria Wendel
Stephanie Victoria Wendel
JWJulius Clemens Heinrich Wilming
Julius Clemens Heinrich Wilming
NANiklas Armbrust
Niklas Armbrust
GWGil Gregor Westmeyer
Gil Gregor Westmeyer
Prime editing (PE) is a powerful gene-editing technique based on targeted gRNA-templated reverse transcription and integration of the de novo synthesized single-stranded DNA. To circumvent one of the main bottlenecks of the method, the competition of the reverse-transcribed 3′ flap with the original 5′ flap DNA, we generated an enhanced fluorescence-activated cell sorting reporter cell line to develop an exonuclease-enhanced PE strategy (‘Exo-PE’) composed of an improved PE complex and an aptamer-recruited DNA-exonuclease to remove the 5′ original DNA flap. Exo-PE achieved better overall editing efficacy than the reference PE2 strategy for insertions ≥30 base pairs in several endogenous loci and cell lines while maintaining the high editing precision of PE2. By enabling the precise incorporation of larger insertions, Exo-PE complements the growing palette of different PE tools and spurs additional refinements of the PE machinery.

21 December 2023 in Advanced Functional Materials
Verified
Journal Article
Open access
MŽMilica Živanić
Milica Živanić
AEAlbert Espona‐Noguera
Albert Espona‐Noguera
HVHanne Verswyvel
Hanne Verswyvel
ESEvelien Smits
Evelien Smits
ABAnnemie Bogaerts
Annemie Bogaerts
CCCristina Canal
Cristina Canal
Cold atmospheric plasma (CAP) is a source of cell‐damaging oxidant molecules that may be used as low‐cost cancer treatment with minimal side effects. Liquids treated with cold plasma and enriched with oxidants are a modality for non‐invasive treatment of internal tumors with cold plasma via injection. However, liquids are easily diluted with body fluids which impedes high and localized delivery of oxidants to the target. As an alternative, plasma‐treated hydrogels (PTH) emerge as vehicles for the precise delivery of oxidants. This study reports an optimal protocol for the preparation of injectable alginate PTH that ensures the preservation of plasma‐generated oxidants. The generation, storage, and release of oxidants from the PTH are assessed. The efficacy of the alginate PTH in cancer treatment is demonstrated in the context of cancer cell cytotoxicity and immunogenicity–release of danger signals and phagocytosis by immature dendritic cells, up to now unexplored for PTH. These are shown in osteosarcoma, a hard‐to‐treat cancer. The study aims to consolidate PTH as a novel cold plasma treatment modality for non‐invasive or postoperative tumor treatment. The results offer a rationale for further exploration of alginate‐based PTHs as a versatile platform in biomedical engineering.

13 June 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
VMVolker Morath
Volker Morath
KFKatja Fritschle
Katja Fritschle
LWLinda Warmuth
Linda Warmuth
MAMarkus Anneser
Markus Anneser
SDSarah Dötsch
Sarah Dötsch
Wolfgang WeberWolfgang Weber
Wolfgang Weber
The clinical translation of cell- and gene-based therapies is limited by the lack of non-invasive, quantitative and specific whole-body imaging tools. Here we present a positron emission tomography reporter system based on a membrane-anchored anticalin protein that binds a fluorine-18-labelled lanthanide complex with picomolar affinity via a bio-orthogonal interaction. The reporter was introduced into therapeutic cells, including CAR T cells and adeno-associated virus-transduced cells. In vitro, reporter expression conferred >800-fold higher radioligand binding versus controls. In mice, the radioligand demonstrated rapid renal clearance, showed no off-target accumulation and enabled high-contrast detection of as few as 1,200 CAR T cells in the bone marrow. Longitudinal positron emission tomography imaging over 4 weeks revealed precise tracking of CAR T cell expansion and migration, with signal intensity correlating linearly with flow cytometry data. The system also enabled the quantitative imaging of in vivo gene transfer using an adeno-associated viral vector. This depth-independent whole-body imaging platform offers a powerful tool for monitoring therapeutic cell dynamics and gene delivery in preclinical and potentially clinical settings.

7 November 2022 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
DTDong-Jiunn Jeffery Truong
Dong-Jiunn Jeffery Truong
NANiklas Armbrust
Niklas Armbrust
JGJulian Geilenkeuser
Julian Geilenkeuser
ELEva-Maria Lederer
Eva-Maria Lederer
TSTobias Heinrich Santl
Tobias Heinrich Santl
GWGil Gregor Westmeyer
Gil Gregor Westmeyer
Despite their fundamental role in assessing (patho)physiological cell states, conventional gene reporters can follow gene expression but leave scars on the proteins or substantially alter the mature messenger RNA. Multi-time-point measurements of non-coding RNAs are currently impossible without modifying their nucleotide sequence, which can alter their native function, half-life and localization. Thus, we developed the intron-encoded scarless programmable extranuclear cistronic transcript (INSPECT) as a minimally invasive transcriptional reporter embedded within an intron of a gene of interest. Post-transcriptional excision of INSPECT results in the mature endogenous RNA without sequence alterations and an additional engineered transcript that leaves the nucleus by hijacking the nuclear export machinery for subsequent translation into a reporter or effector protein. We showcase its use in monitoring interleukin-2 (IL2) after T cell activation and tracking the transcriptional dynamics of the long non-coding RNA (lncRNA) NEAT1 during CRISPR interference-mediated perturbation. INSPECT is a method for monitoring gene transcription without altering the mature lncRNA or messenger RNA of the target of interest.

14 August 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
MŽMilica Živanić
Milica Živanić
AEAlbert Espona-Noguera
Albert Espona-Noguera
Angela Privat MaldonadoAngela Privat Maldonado
Angela Privat Maldonado
PMPatrik Matušů
Patrik Matušů
FTFrancesco Tampieri
Francesco Tampieri
Cristina CanalCristina Canal
Cristina Canal
Oxidative stress‐based therapies exploit common cancer traits—elevated reactive oxygen species and altered redox metabolism,—making tumors more susceptible to oxidative damage from, e.g., cold atmospheric plasma, an ionized gas containing reactive oxygen and nitrogen species (RONS). Plasma‐treated hydrogels (PTH) emerge as vehicles for RONS delivery. Here, PTH are explored as single vehicle for the combined local delivery of RONS and Doxorubicin (Dox). Dox does not impair PTH function, and its IC50 is lowered in vitro; biological characterization and monotherapy comparison are conducted in ovo . Analysis of over 200 tumors, derived from liposarcoma SW872 or osteosarcoma 143B cell lines, reveals effects in the latter after a single PTH‐Dox administration: synergistic GPX4 reduction, with the fraction of high cytoplasmic GPX4 cells dropping from 47% to 24%, and diminished average tumor weight, with multiple tumors (of smaller initial size) weighting 70% less than control. In contrast, mono‐therapies enhanced the protective GPX4/NRF2 mRNA or protein expression. GPX4 is a ferroptosis inhibitor linked to therapy resistance. Observing effects after a single PTH‐Dox hydrogel administration is exceptional, as indirect plasma treatment has until now required frequent dosing in complex tumor models. For clinical use, multimodal approaches are key, and PTHs offer a convenient platform.